Kamakshi V Rao1, Aimee Faso2. 1. Oncology/BMT clinical pharmacist practitioner, University of North Carolina Hospitals and Clinics, Chapel Hill, NC. 2. Hematology/oncology clinical pharmacist practitioner, University of North Carolina Hospitals and Clinics, Chapel Hill, NC.
Abstract
BACKGROUND: Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients. OBJECTIVE: To discuss CINV and the current pharmacologic approaches to its management. DISCUSSION: This article outlines the mechanism of CINV followed by a review of current approaches to pharmacologic therapy and current practice guidelines from national cancer organizations. This information will help providers and payers understand the optimal management of patients with CINV including practical considerations and value-based decision-making that considers cost issues. CONCLUSION: Numerous preventive and treatment options are available to manage CINV Addressing antiemetic regimens requires ongoing patient evaluation to determine the best approach for each individual patient.
BACKGROUND:Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients. OBJECTIVE: To discuss CINV and the current pharmacologic approaches to its management. DISCUSSION: This article outlines the mechanism of CINV followed by a review of current approaches to pharmacologic therapy and current practice guidelines from national cancer organizations. This information will help providers and payers understand the optimal management of patients with CINV including practical considerations and value-based decision-making that considers cost issues. CONCLUSION: Numerous preventive and treatment options are available to manage CINV Addressing antiemetic regimens requires ongoing patient evaluation to determine the best approach for each individual patient.
Authors: T Endo; M Minami; M Hirafuji; T Ogawa; K Akita; M Nemoto; H Saito; M Yoshioka; S H Parvez Journal: Toxicology Date: 2000-11-16 Impact factor: 4.221
Authors: Eyal Meiri; Haresh Jhangiani; James J Vredenburgh; Luigi M Barbato; Frederick J Carter; Hwa-Ming Yang; Vickie Baranowski Journal: Curr Med Res Opin Date: 2007-03 Impact factor: 2.580
Authors: R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro Journal: Ann Oncol Date: 2003-10 Impact factor: 32.976
Authors: J Latreille; D Stewart; F Laberge; P Hoskins; J Rusthoven; E McMurtrie; D Warr; L Yelle; D Walde; F Shepherd Journal: Support Care Cancer Date: 1995-09 Impact factor: 3.603
Authors: Komal P Singh; Anand A Dhruva; Elena Flowers; Kord M Kober; Christine Miaskowski Journal: Crit Rev Oncol Hematol Date: 2017-11-20 Impact factor: 6.312
Authors: Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton Journal: Br J Haematol Date: 2020-02-23 Impact factor: 8.615
Authors: Alaa A M Osman; Moawia M A Elhassan; Blala H A AbdElrahim; Fatima H A Ahmed; Jihad B H Yousif; Malak A M Ahmed; Romisa H A Abdelhafeez; Umsalama M Y Ahmed Journal: J Glob Oncol Date: 2018-09